Taketo et al. reported that a METTL3-knockdown pancreatic cancer cell line showed higher sensitivity to anticancer agents such as gemcitabine, 5-fluorouracil, cisplatin, and irradiation, suggesting that METTL3 is a potential target for the enhancement of therapeutic efficacy (25). The gene discussed is METTL3; the disease is familial pancreatic carcinoma.